SAB Biotherapeutics (SABS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SABS SAB Biotherapeutics

Watchlist

3.0100
+0.2500+9.06%

Close Oct 18 16:00 ET

2.8600
-0.1500-4.98%

Post 20:02 ET

27.78MMarket Cap-488P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Friday's After-Market Session
BenzingaOct 18 16:30 ET
Craig-Hallum Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11
Moomoo NewsOct 14 09:31 ET · Ratings
Craig-Hallum Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $11
Moomoo NewsOct 9 08:31 ET · Ratings
SAB Biotherapeutics Initiated With a Buy at Craig-Hallum
TipRanksOct 9 07:26 ET · Ratings
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
Yahoo FinanceSep 23 10:53 ET
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
GlobeNewswireSep 13 07:00 ET

Comments

Only Believe

Oct 16 13:35

$SAB Biotherapeutics (SABS.US)$
Keep Watch 👀

Clintzilla

Sep 20 13:22

$SAB Biotherapeutics (SABS.US)$ sneaky sneaky..

Jaguar8

Sep 9 06:02

NEWS

$SAB Biotherapeutics (SABS.US)$
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study.
Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness.
SAB-142 remains on track for a topline Phase 1 data readout by the end of the ye...

Trytosaveabit

May 21 06:16

News

$SAB Biotherapeutics (SABS.US)$ Reuters· just
FDA Provides Clearance to Ind Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

Jaguar8

May 21 06:15

$SAB Biotherapeutics (SABS.US)$
NEWS
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmac...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

SABS SAB Biotherapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target